Abstracts tagged "spondyloarthritis"

Abstract Number: 0447 • ACR Convergence 2025
Foot-pressure distribution method for detection of foot joint arthritis in patients with rheumatic diseases
Hayagrivas Manicka Bharathkumar¹, Emani Srinija Reddy¹, Bhaskar Pandey², Suryansh Saini¹, Sangeet Rathi¹, Saransh Verma¹, Chinmay Prakash Swami², Deepak Joshi² and Ranjan Gupta¹, ¹All India Institute of Medical Sciences (AIIMS), New Delhi, Delhi, Delhi, India, ²Indian Institute of Technology (IIT), Delhi, Delhi, Delhi, India
Background/Purpose: Rheumatoid arthritis (RA) and Seronegative Spondyloarthritis (SSA), the most common types of inflammatory arthritis, have significant ankle and foot joint involvement. However, these joints…
Abstract Number: 1415 • ACR Convergence 2025
The Association of Handedness with Radiographic Damage in Patients with Psoriatic Arthritis
Fadi Kharouf¹, Shahad Al-Matar², Virginia Carrizo Abarza³, Pankti Mehta⁴, Shangyi Gao⁵, Daniel Pereira⁶, Richard Cook⁷, Vinod Chandran⁸, Denis Poddubnyy⁹ and Dafna D. Gladman¹⁰, ¹University Health Network and University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada, ²University of alberta, Edmonton, AB, Canada, ³Toronto Western Hospital - University of Toronto, Toronto, ON, Canada, ⁴University of Toronto, Gladman Krembil Psoriatic Arthritis Research Program, Toronto, ON, Canada, ⁵Gladman-Krembil Psoriatic Arthritis Research Program, Centre for Prognosis Studies in the Rheumatic Diseases, Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, Ontario, Canada, Toronto, ON, Canada, ⁶University Health Network, Toronto, ON, Canada, ⁷University of Waterloo, Waterloo, Canada, ⁸University of Toronto, Toronto, ON, Canada, ⁹Division of Rheumatology, Department of Medicine, University Health Network and University of Toronto, Toronto, Ontario, Canada, and Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany; Department of Epidemiology, German Rheumatism Research Centre, Berlin, Germany, ¹⁰Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada
Background/Purpose: Mechanical stress is known to trigger and exacerbate psoriatic arthritis (PsA). Based on the hypothesis that biomechanical stress is greater in the dominant extremity,…
Abstract Number: 2358 • ACR Convergence 2025
Bimekizumab Demonstrated Early and Sustained Efficacy Regardless of Baseline Characteristics in Patients with Active Psoriatic Arthritis: Pooled Post Hoc Results up to 1-Year from Two Phase 3 Studies
Lihi Eder¹, Philip J. Mease², Iain McInnes³, M. Elaine Husni⁴, Mitsumasa Kishimoto⁵, Barbara Ink⁶, Rajan Bajracharya⁶, Jason Coarse⁷ and Fabian Proft⁸, ¹University of Toronto, Toronto, ON, Canada, ²Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ³University of Glasgow, Glasgow, United Kingdom, ⁴Department of Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ⁵Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, ⁶UCB, Slough, England, United Kingdom, ⁷UCB, Morrisville, NC, ⁸Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
Background/Purpose: Bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)‑17F in addition to IL‑17A, has demonstrated clinical efficacy and safety to 3 years…
Abstract Number: 2320 • ACR Convergence 2025
Sleep Disturbance in Psoriatic Arthritis: Prevalence by Minimal Disease Activity Status and Associated Clinical Factors
Lourdes Perez Chada¹, Vivi Feather², Grace Carter², Helen Early³, Emily Tsai², Jing Cui⁴, Avery LaChance⁵, Rochelle Castillo⁶, Neda shahriari², Alexis Ogdie⁷, Monika Haack², Elizabeth Klerman², Michael Weinblatt⁸, Nancy Shadick⁹, Joseph Merola¹⁰ and Chinmayi Naik³, ¹Harvard Medical School, Wayland, MA, ²Mass General Brigham, Boston, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Brigham Women's Hospital, Boston, MA, ⁵Brigham and Women's Hospital, Jamaica Plain, MA, ⁶Brigham and Women's Hospital, Brookline, MA, ⁷Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Wilmington, DE, ⁸Brigham and Women's Hospital/ Harvard Medical School, Waban, MA, ⁹Brigham & Women's Hospital, Boston, MA, ¹⁰UT Southwestern Medical Center, Dallas, TX
Background/Purpose: Sleep disturbance is a common and burdensome symptom in psoriatic arthritis (PsA), but its clinical determinants remain poorly understood. Using data from the Cohort…
Abstract Number: 1930 • ACR Convergence 2025
Can a Multinational Awareness Campaign Improve Referral Rates and Reduce Diagnostic Delays in Patients with Chronic Inflammatory Rheumatic Diseases? The Impact of a Prospective Interventional Study
Nelly Ziade¹, Karen Mechleb², Fatima Alnaimat³, Sherif Gamal⁴, Avin Maroof⁵, Bassel Elzorkany⁶, Manal Mashaleh⁷, Manal El Rakawi⁸, Mahmoud Adly⁹, Lina Elkibbi¹⁰, ERRAOUI Mariam¹¹, Krystel Aouad¹², Chafika Haouichat¹³, Nizar Abdullateef¹⁴, ASAL ADNAN RIDHA¹⁵, Fatemah Baron¹⁶ and Ihsane Hmamouchi¹⁷, ¹Department of Rheumatology, Saint-Joseph University and Hotel-Dieu de France, Beirut, Lebanon, ²Saint Joseph University Beirut, Beirut, Lebanon, ³The University of Jordan, amman, Jordan, ⁴Cairo University, Cairo, Egypt, ⁵University of Kurdistan Hawler, Erbil, Iraq, ⁶Private (BZRC), Cairo, Egypt, ⁷Al Saudi Hospital, Amman, Jordan, ⁸Djillali Bounaama University Hospital, Algiers, Algeria, Algiers, Algeria, ⁹Ministry of Health, Kuwait, Kuwait, Saad Elabdulla, Kuwait, ¹⁰Specialized Medical Center, Riyadh, Saudi Arabia, Riyadh, Saudi Arabia, ¹¹CHU Agadir, Agadir, Morocco, ¹²Department of Rheumatology, Saint George Hospital University Medical Center, Beirut, Lebanon, ¹³Djillali Bounaama University Hospital, Algiers, Algeria, ¹⁴Baghdad College of Medicine, Baghdad, Iraq, ¹⁵Baghdad Teaching Hospital, Baghdad, Iraq, ¹⁶Al-Jahra Hospital, Kuwait, Kuwait, Kuwait, Kuwait, ¹⁷Health Sciences Research Center (CReSS).Faculty of Medicine, International University of Rabat, Rabat, Morocco
Background/Purpose: Delayed diagnosis and treatment in chronic inflammatory rheumatic diseases (CIRDs), including rheumatoid arthritis (RA), axial spondyloarthritis (axSpA), and psoriatic arthritis (PsA), is associated with…
Abstract Number: 1435 • ACR Convergence 2025
Impact of Treatment With Upadacitinib on Non-Nociceptive Pain and Its Relevance for the Presence of Residual Symptoms in Axial Spondyloarthritis: Results from a Multicountry Observational Study
Denis Poddubnyy¹, Victoria Navarro-Compan², Neil Basu³, Mohammad Naffaa⁴, Tianming Gao⁵, Christopher Saffore⁶, Jamie Urbanik⁷, Bhumik Parikh⁸, Peter Taylor⁹ and Philip J. Mease¹⁰, ¹Division of Rheumatology, Department of Medicine, University Health Network and University of Toronto, Toronto, Ontario, Canada, and Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany; Department of Epidemiology, German Rheumatism Research Centre, Berlin, Germany, ²Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, ³Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, United Kingdom, ⁴The Azriel's Faculty of Medicine, Bar-Ilan University, Safed, Israel; The Rheumatology Unity, Galilee Medical Center, Naharyia, Israel, ⁵AbbVie, North Chicago, IL, ⁶AbbVie Inc., waukegan, IL, ⁷AbbVie, Grayslake, IL, ⁸AbbVie, Hillsborough Township, NJ, ⁹University of Oxford, Oxford, United Kingdom, ¹⁰Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA
Background/Purpose: Upadacitinib (UPA), an oral JAK inhibitor, has demonstrated improvements in inflammation and nociceptive pain in late phase clinical trials of patients with axSpA.1,2,3 However,…
Abstract Number: 0592 • ACR Convergence 2025
An Interim Analysis of Health-Related Quality of Life Outcomes from an International Multicentre Observational Study in Patients with Axial Spondyloarthritis Initiating Bimekizumab in Real-World Clinical Practice
Xenofon Baraliakos¹, Uta Kiltz¹, Kurt de Vlam², Adeline Ruyssen-Witrand³, Julio Ramírez Garcia⁴, Jessica A. Walsh⁵, Denis Poddubnyy⁶, David Nicholls⁷, Marga Oortgiesen⁸, Francesca Maria Ester Castagna⁹, Marie-Alix Bonny¹⁰, Hervé Besson¹¹, Rajan Bajracharya¹², Patrik Öhagen¹³, Christine de La Loge¹⁰ and William Tillett¹⁴, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ²Department of Rheumatology, UZ Leuven, Leuven, Belgium, ³CHU of Toulouse - Pierre-Paul Riquet Hospital (Inflammation, Infection, Immunology and Locomotor Center - Rheumatology Service, Toulouse, France, ⁴Rheumatology Department, Hospital Clinic and IDIBAPS of Barcelona, Barcelona, Spain, ⁵Division of Rheumatology, Salt Lake City Veterans Affairs Health and University of Utah Health, Salt Lake City, UT, ⁶Division of Rheumatology, Department of Medicine, University Health Network and University of Toronto, Toronto, Ontario, Canada, and Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany; Department of Epidemiology, German Rheumatism Research Centre, Berlin, Germany, ⁷Clinical Trials Unit, University of the Sunshine Coast, Queensland, Australia, ⁸UCB, Raleigh, NC, ⁹UCB SpA, Milano, Italy, ¹⁰UCB, Brussels, Belgium, ¹¹UCB, Breda, Netherlands, ¹²UCB, Slough, England, United Kingdom, ¹³UCB, Stockholm, Sweden, ¹⁴Department of Life Sciences, Centre for Therapeutic Innovation, University of Bath, Bath, United Kingdom
Background/Purpose: Axial spondyloarthritis (axSpA) is a chronic inflammatory disease with a significant burden on patients’ (pts) health-related quality of life (HRQoL).1 Bimekizumab (BKZ), a monoclonal…
Abstract Number: 0544 • ACR Convergence 2025
Prevalence and Baseline Characteristics associated with Difficult-to-Manage Axial Spondyloarthritis in the DESIR Cohort
Olivier Fakih¹, Anna Molto², Frank Verhoeven¹, Clément Prati¹ and WENDLING Daniel¹, ¹CHU de Besançon, Besançon, Franche-Comte, France, ²Assistance Publique Hôpitauxde Paris, Paris, France
Background/Purpose: Despite a choice of multiple targeted DMARDs, with different modes of action (MoA), a number of patients with axial spondyloarthritis (axSpA) have failed several…
Abstract Number: 0428 • ACR Convergence 2025
The OMERACT Juvenile Idiopathic Arthritis MRI Score for Active and Structural Lesions in the Sacroiliac Joints: Development and Validation in Two Longitudinal Cohorts
Walter P. Maksymowych¹, Michael Francavilla², Nele Herregods³, Robert G. W. Lambert⁴, Arthur Meyers⁵, Joel Paschke⁶, Jennifer Stimec⁷, Pamela Weiss⁸ and Dax Rumsey⁹, ¹Department of Medicine, University of Alberta, ⁵⁶⁸ Heritage Building, Edmonton, AB, Canada, ²Department of Pediatric Radiology, Children’s Hospital Philadelphia, Philadelphia, PA, ³Department of Pediatric Radiology, Ghent University Hospital, Ghent, Belgium, ⁴University of Alberta, Department of Radiology & Diagnostic Imaging, Edmonton, AB, Canada, ⁵Department of Radiology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ⁶CARE Arthritis Limited, Edmonton, AB, Canada, ⁷Department of Diagnostic Imaging, SickKids, University of Toronto, Toronto, Canada, ⁸Childrens Hospital of Philadelphia, Philadelphia, PA, ⁹Department of Pediatrics, University of Alberta, Edmonton, AB, Canada
Background/Purpose: The OMERACT Juvenile Idiopathic Arthritis MRI (JAMRIS) Working group has defined a spectrum of MRI lesions in the sacroiliac joint (SIJ) in youth with…
Abstract Number: 2359 • ACR Convergence 2025
Combination Of TNF Inhibitors And NSAIDs Versus TNF Inhibitors Alone On The Progression Of Structural Damage In The Spine And Hip: a Retrospective Study In 262 Patients With Radiographic Axial Spondyloarthritis
MARIA KONSTA¹, Michael Nurmohamed², Alexios Iliopoulos³, Petros Sfikakis⁴, Ingrid Visman⁵, Grigorios Sakellariou⁶ and Irene E. van der Horst-Bruinsma⁷, ¹Sismanoglion Hospital, Athens, Greece, Marousi, Attiki, Greece, ²Amsterdam Rheumatology and Immunology Center, Reade; Department of Rheumatology and Amsterdam Rheumatology Center, Amsterdam University Medical Centers, Amsterdam, Netherlands, ³⁴¹⁷ Army Share Fund Hospital (NIMTS), Department of Rheumatology, Athens, Greece, ZOGRAFOU, Greece, ⁴NKUA - SCHOOL OF MEDICINE, Athens, Greece, ⁵Reade Amsterdam, Amsterdam, Noord-Holland, Netherlands, ⁶⁴²⁴ General Military Hospital, Thessaloniki, Greece, ⁷Department of Rheumatology, Radboud University Medical Centre, Nijmegen, Netherlands
Background/Purpose: The inhibitory effect of TNF inhibitor (TNFi) treatment on spinal radiographic progression in patients with radiographic Axial Spondyloarthritis (r-axSpA), remains controversial. However, current evidence…
Abstract Number: 2319 • ACR Convergence 2025
Reducing selection bias while maintaining precision through an integrated analysis: 2-year longitudinal analysis of imaging outcomes in the SPondyloArthritis Caught Early cohort
Liese de Bruin¹, Floris A. van Gaalen¹, Manouk de Hooge², Miranda van Lunteren¹, Mary Lucy Marques³, Monique Reijnierse⁴, Roberta Ramonda⁵, Inger Jorid Berg⁶, Carl Turesson⁷, Robert Landewé⁸, Désirée Van Der Heijde¹ and Sofia Ramiro⁹, ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Department of Rheumatology, Ghent University Hospital, Ghent, Belgium, ³Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands; and Coimbra Local Health Unit, Coimbra, Portugal, ⁴Department of Radiology, Leiden University Medical Center, Leiden, Netherlands, ⁵Rheumatology Unit-DIMED-University of Padova ITALY, Padova, Padua, Italy, ⁶⁶Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Nepal, ⁷Lund University, Malmö, Sweden, ⁸Department of Rheumatology, Amsterdam University Medical Center, Amsterdam, Netherlands; and Zuyderland Medical Center, Heerlen, Netherlands, ⁹Leiden University Medical Center, Bunde, Netherlands
Background/Purpose: Imaging outcomes in ongoing cohort studies are typically evaluated across multiple reading rounds by several readers. Often, only scores from the most recent reading…
Abstract Number: 1815 • ACR Convergence 2025
New-Onset Juvenile Spondyloarthritis is Characterized by Bone Metabolism Disturbances with Biomarker Potential
Brittney Newby¹, Timothy Brandon¹, Pamela Weiss² and E. John Wherry³, ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²Childrens Hospital of Philadelphia, Philadelphia, PA, ³University of Pennsylvania, Philadelphia, PA
Background/Purpose: Juvenile spondyloarthritis (JSpA) management is hindered by the lack of reliable biomarkers to predict which patients will develop progressive structural changes, such as erosions…
Abstract Number: 1434 • ACR Convergence 2025
Safety of Prescription NSAIDs in Adults with IBD: Data from a Large Administrative Claims Cohort
Adam Mayer¹, Rui Xiao², Meenakshi Bewtra³, Michael George⁴ and Pamela Weiss⁵, ¹University of Pennsylvania/Children's Hospital of Philadelphia, Philadelphia, PA, ²Children's Hospital of Philadelphia, Philadelphia, PA, ³University of Pennsylvania, Philadelphia, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Childrens Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: The potential that nonsteroidal anti-inflammatory drugs (NSAIDs) may precipitate flares of inflammatory bowel disease (IBD) has limited their use in managing joint pain in…
Abstract Number: 0591 • ACR Convergence 2025
An Interim Analysis of Health-Related Quality of Life Outcomes from an International Multicentre Observational Study in Patients with Psoriatic Arthritis Initiating Bimekizumab in Real-World Clinical Practice
Xenofon Baraliakos¹, Uta Kiltz¹, Kurt de Vlam², Adeline Ruyssen-Witrand³, Felipe Julio Ramirez Garcia⁴, Jessica A. Walsh⁵, Denis Poddubnyy⁶, David Nicholls⁷, Marga Oortgiesen⁸, Francesca Maria Ester Castagna⁹, Marie-Alix Bonny¹⁰, Hervé Besson¹¹, Jérémy Lambert¹², Rajan Bajracharya¹³, Patrik Öhagen¹⁴ and William Tillett¹⁵, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ²Department of Rheumatology, UZ Leuven, Leuven, Belgium, ³CHU of Toulouse - Pierre-Paul Riquet Hospital (Inflammation, Infection, Immunology and Locomotor Center - Rheumatology Service, Toulouse, France, ⁴Rheumatology Department, Hospital Clinic and IDIBAPS of Barcelona, Barcelona, Spain, ⁵Division of Rheumatology, Salt Lake City Veterans Affairs Health and University of Utah Health, Salt Lake City, UT, ⁶Division of Rheumatology, Department of Medicine, University Health Network and University of Toronto, Toronto, Ontario, Canada, and Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany; Department of Epidemiology, German Rheumatism Research Centre, Berlin, Germany, ⁷Clinical Trials Unit, University of the Sunshine Coast, Queensland, Australia, ⁸UCB, Raleigh, NC, ⁹UCB SpA, Milano, Italy, ¹⁰UCB, Brussels, Belgium, ¹¹UCB, Breda, Netherlands, ¹²UCB, Colombes, France, ¹³UCB, Slough, England, United Kingdom, ¹⁴UCB, Stockholm, Sweden, ¹⁵Department of Life Sciences, Centre for Therapeutic Innovation, University of Bath, Bath, United Kingdom
Background/Purpose: PsA is a chronic inflammatory disease with a significant burden on patients’ (pts) health-related quality of life (HRQoL).1 Bimekizumab (BKZ), a monoclonal IgG1 antibody…
Abstract Number: 0545 • ACR Convergence 2025
Temporal trends in the phenotype and treatment outcomes in axial spondyloarthritis patients included in randomized clinical trials over 25 years: a systematic literature review and meta-regression analysis
Omar-Javier Calixto¹, Uta Kiltz², Brikena Lalazi³, Franziska Neinert³, Philipp Sewerin⁴ and Xenofon Baraliakos², ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Cellular and Molecular Immunology Group (InmuBo), Universidad El Bosque, Herne, Nordrhein-Westfalen, Germany, ²Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ³Rheumazentrum Ruhrgebiet, Herne, Germany, ⁴Rheumazentrum Ruhrgebiet Herne; Ruhr-Universität Bochum, Germany, Herne, Germany
Background/Purpose: The phenotypes of axial spondyloarthritis (axSpA) and clinical responses to placebo and study drugs in randomized controlled trials (RCTs) have changed over time. We…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].